Interstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-hodgkin lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 6, 2011, Pages 483-489

  Kato, Harumi ^a   Yamamoto, Kazuhito ^a   Taji, Hirofumi ^a   Oki, Yasuhiro ^a   Chihara, Dai ^a   Seto, Masao ^a   Kagami, Yoshitoyo ^a   Morishima, Yasuo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Autologous stem cell transplantation; Immunochemotherapy; Interstitial pneumonia; Malignant lymphoma; Rituximab; Toxicity

Indexed keywords

ACICLOVIR; CARBOPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MITOXANTRONE; QUINOLONE; RANIMUSTINE; RITUXIMAB;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PNEUMOCYSTIS PNEUMONIA; RETROSPECTIVE STUDY; RISK FACTOR; TOTAL BODY IRRADIATION CONDITIONING;

EID: 84860620775     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.06.011     Document Type: Article

References (29)

1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-45. (Pubitemid 24030569)
2. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116:2040-5.
3. Oki Y, Ogura M, Kato H, et al. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Sci 2008; 99:179-84. (Pubitemid 350239048)
4. van OersMH,Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28:2853-8.
5. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non- Hodgkin lymphoma. Blood 2004; 103:777-83. (Pubitemid 38129532)
6. Kato H, Taji H, Ogura M, et al. Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma. Clin Lymphoma Myeloma 2009; 9:443-8.
7. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112:2687-93.
8. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10:816-24.
9. Ram R, Ben-Bassat I, Shpilberg O, et al. The late adverse events of rituximab therapy - rare but there! Leuk Lymphoma 2009; 50:1083-95.
10. Liote H, Liote F, Seroussi B, et al. Rituximab-induced lung disease: a systematic literature review. Eur Respir J 2010; 35:681-7.
11. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007; 82:916-9. (Pubitemid 47502698)
12. Liu X, Hong XN, Gu YJ, et al. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 2008; 49: 1778-83.
13. Katsuya H, Suzumiya J, Sasaki H, et al. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50:1818-23.
14. Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:2208-14. (Pubitemid 46218712)
15. Ruiz-Soto R, Sergent G, Gisselbrecht C, et al. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients. Cancer 2005; 104:2735-42. (Pubitemid 41798283)
16. Kato H, Yamamoto K, Matsuo K, et al. Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events. Ann Oncol 2010; 21:1699-705.
17. Wingard JR, Sostrin MB, Vriesendorp HM, et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1988; 46:61-5.
18. Jochelson M, Tarbell NJ, Freedman AS, et al. Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 1990; 6:329-31.
19. Drake C, Fisher L. Prognostic models and the propensity score. Int J Epidemiol 1995; 24:183-7.
20. Heresi GA, Farver CF, Stoller JK. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration 2008; 76:449-53.
21. Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003; 348:2690-1. (Pubitemid 36741603)
22. Ennishi D, Terui Y, Yokoyama M, et al. Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 2008; 87:393-7.
23. Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006; 91:496-502.
24. Kolstad A, Holte H, Fossa A, et al. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007; 92:139-40. (Pubitemid 46232678)
25. Maeda S, Kagami Y, Ogura M, et al. CD34-selected autologous peripheral blood stem cell transplantation conditioned with total body irradiation for malignant lymphoma: increased risk of infectious complications. Int J Hematol 2001; 74:214-21. (Pubitemid 33760075)
26. Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1-112.
27. Pagano L, Fianchi L, Mele L, et al. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol 2002; 117:379-86. (Pubitemid 34451154)
28. Bienvenu J, Chvetzoff R, Salles G, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2001; 2:378-84. (Pubitemid 34048661)
29. Shelton E, Yong M, Cohney S. Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology (Carlton) 2009; 14:696-9.